T Santantonio

Summary

Affiliation: University of Bari
Country: Italy

Publications

  1. ncbi request reprint Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis
    T Santantonio
    Heinrich Pette Institut fur experimentelle Virologie und Immunologie an der Universitat Hamburg, Germany
    Hepatogastroenterology 46:1848-54. 1999
  2. doi request reprint Acute hepatitis C: current status and remaining challenges
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Bari, Policlinico, Bari, Italy
    J Hepatol 49:625-33. 2008
  3. ncbi request reprint Therapy of acute hepatitis C: a review of literature
    T Santantonio
    Clinic of Infectious Diseases, University of Bari, Italy
    Curr Pharm Des 14:1686-9. 2008
  4. ncbi request reprint Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy
    T Santantonio
    Clinic of Infectious Diseases, University of Bari, Bari, Italy
    Clin Infect Dis 43:1154-9. 2006
  5. ncbi request reprint Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Bari, Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy
    J Hepatol 42:329-33. 2005
  6. ncbi request reprint Treatment of acute hepatitis C
    T Santantonio
    Clinical of Infectious Diseases, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    Curr Pharm Des 10:2077-80. 2004
  7. ncbi request reprint Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study
    Teresa Santantonio
    Department of Internal Medicine, Immunology and Infectious Diseases, University of Bari, Bari, Italy
    J Hepatol 36:799-804. 2002
  8. ncbi request reprint Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
    T Santantonio
    Clinica Malattie Infettive Università di Bari, Italy
    J Hepatol 32:300-6. 2000
  9. ncbi request reprint Natural course of acute hepatitis C: a long-term prospective study
    T Santantonio
    Department of Clinical Medicine, Immunology and Infectious Diseases, University of Bari, Bari, Italy
    Dig Liver Dis 35:104-13. 2003
  10. ncbi request reprint Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Foggia, Ospedali Riuniti, Foggia, Italy
    Antivir Ther 14:557-65. 2009

Detail Information

Publications20

  1. ncbi request reprint Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis
    T Santantonio
    Heinrich Pette Institut fur experimentelle Virologie und Immunologie an der Universitat Hamburg, Germany
    Hepatogastroenterology 46:1848-54. 1999
    ....
  2. doi request reprint Acute hepatitis C: current status and remaining challenges
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Bari, Policlinico, Bari, Italy
    J Hepatol 49:625-33. 2008
    ..We also discuss data from published clinical studies and focus on unresolved issues for which additional studies are needed in order to establish standardized treatment guidelines for the management of acute hepatitis C...
  3. ncbi request reprint Therapy of acute hepatitis C: a review of literature
    T Santantonio
    Clinic of Infectious Diseases, University of Bari, Italy
    Curr Pharm Des 14:1686-9. 2008
    ..Ongoing randomized controlled clinical trials should focus on unresolved questions and definitely establish the optimal treatment for acute hepatitis C...
  4. ncbi request reprint Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy
    T Santantonio
    Clinic of Infectious Diseases, University of Bari, Bari, Italy
    Clin Infect Dis 43:1154-9. 2006
    ..The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated...
  5. ncbi request reprint Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Bari, Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy
    J Hepatol 42:329-33. 2005
    ....
  6. ncbi request reprint Treatment of acute hepatitis C
    T Santantonio
    Clinical of Infectious Diseases, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    Curr Pharm Des 10:2077-80. 2004
    ..However, additional data are required to improve the selection of those patients at great risk of progressing to chronic disease, and also to establish the optimal treatment in terms of risk/benefit and cost-effectiveness ratio...
  7. ncbi request reprint Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study
    Teresa Santantonio
    Department of Internal Medicine, Immunology and Infectious Diseases, University of Bari, Bari, Italy
    J Hepatol 36:799-804. 2002
    ..In this study, lamivudine-interferon (LAM/IFN) combination therapy was compared to LAM monotherapy to verify if the combination treatment might improve efficacy and reduce the emergence of LAM-resistant mutants...
  8. ncbi request reprint Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
    T Santantonio
    Clinica Malattie Infettive Università di Bari, Italy
    J Hepatol 32:300-6. 2000
    ..The aim of this study was to verify the long-term efficacy of lamivudine treatment of these patients and the incidence of lamivudine-resistant hepatitis B virus mutants...
  9. ncbi request reprint Natural course of acute hepatitis C: a long-term prospective study
    T Santantonio
    Department of Clinical Medicine, Immunology and Infectious Diseases, University of Bari, Bari, Italy
    Dig Liver Dis 35:104-13. 2003
    ....
  10. ncbi request reprint Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B
    Teresa Santantonio
    Clinic of Infectious Diseases, University of Foggia, Ospedali Riuniti, Foggia, Italy
    Antivir Ther 14:557-65. 2009
    ..Risk factors for ADV resistance were also evaluated...
  11. ncbi request reprint Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Mario Rizzetto
    Experimental Department of Gastroenterology, San Giovanni Battista Hospital C So Bramante, 88 10126 Turin, Italy
    J Hepatol 42:173-9. 2005
    ..The histological and clinical outcome of lamivudine 100mg/day was assessed in 76 HBeAg-negative chronic hepatitis B patients previously randomised to a double-blind comparison study of lamivudine and placebo...
  12. ncbi request reprint Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
    Vito Di Marco
    Cattedra e U O C di Gastroenterologia, Clinica Medica, Universita di Palermo, Palermo, Italy
    Hepatology 40:883-91. 2004
    ..After 4 years of therapy, 39% of patients maintain a virological and biochemical response. Loss of virological response may lead to clinical deterioration in patients with cirrhosis...
  13. ncbi request reprint Hepatitis B surface antigen clearance in lamivudine-treated patients: main therapeutic goal?
    Teresa Santantonio
    Gastroenterology 132:2617; author reply 2617-8. 2007
  14. ncbi request reprint Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    Savino Bruno
    Liver Unit, Department of Medicine, AO Fatebenefratelli e Oftalmico, Milan, Italy
    Hepatology 45:579-87. 2007
    ..Irrespective of SVR achievement, all patients should continue surveillance because the risk of occurrence of HCC was not entirely avoided...
  15. ncbi request reprint The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
    Massimo Puoti
    Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy
    Antivir Ther 9:811-7. 2004
    ..3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen...
  16. ncbi request reprint Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection
    Axel Ulsenheimer
    Institute for Immunology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Hepatology 41:643-51. 2005
    ..In cHC there is incomplete recovery of pDC function, which, however, could be solely due to the chronic inflammatory state...
  17. ncbi request reprint A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili di Brescia, Universita di Brescia, Brescia, Italy
    J Hepatol 41:312-8. 2004
    ..To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients...
  18. ncbi request reprint Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon
    Teresa Santantonio
    J Hepatol 45:759-61. 2006
  19. ncbi request reprint Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C
    Giuseppina Raffa
    Unit of Clinical and Molecular Hepatology, Department of Internal Medicine, University of Messina, Italy
    AIDS 21:2171-5. 2007
    ....
  20. ncbi request reprint Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides
    Maria G Isaguliants
    Department of Virology, Swedish Institute for Infectious Disease Control, Stockholm, Sweden
    J Med Virol 66:204-17. 2002
    ..A tendency was observed for a slower development of anti-HVR1 antibody response in patients developing chronic HCV, as compared to those with self-limiting HCV infection...